McGuff Compounding Pharmacy Services, Inc., Santa Ana, CA
Is McGuff Compounding Pharmacy Services, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does McGuff Compounding Pharmacy Services, Inc. hold a California pharmacy license?
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. The Colorado State Board of Pharmacy also lists nonresident license OSP 5146 for McGuff Compounding Pharmacy Services Inc, Santa Ana, CA, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054014270 for MCGUFF COMPOUNDING PHARMACY SERVICES INC, SANTA ANA, CA, status RELINQUISH, as of Nov 13, 2026.
Has McGuff Compounding Pharmacy Services, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (May 29, 2020) and 1 FMD-145 letter (May 29, 2020) for McGuff Compounding Pharmacy Services, Inc. State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists 2 actions: “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Mar 1, 2023, case AC 7176 on license PHY 43950 and “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Mar 1, 2023, case AC 7176 on license LSC 99004. The Illinois Department of Financial and Professional Regulation’s license dataset also lists 2 actions: “Surrender (Relinquish)” dated Nov 4, 2023, case 2021011404 on nonresident license 054014270 and “Reprimand” dated Nov 5, 2019, case 2018003510 on nonresident license 054014270. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- McGuff Compounding Pharmacy Services, Inc.
- Location
- Santa Ana, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- May 29, 2020
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 7 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as McGuff Compounding Pharmacy Services, Inc., a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| May 29, 2020 | State referral letter | State Referral Letter Issued 05/29/2020 | Not linked by FDA |
| May 29, 2020 | FMD-145 letter | FMD-145 Letter Issued 05/29/2020 | FDA copy (archived) |
| Nov 22, 2019 | Form 483 | 483 Issued 11/22/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 12, 2019 to Nov 22, 2019: 7 observations
- Firm on the cover
- McGuff Compounding Pharmacy Services, Inc., 2921 W Macarthur Blvd Ste 142, Santa Ana, CA 92704 -7944
- FEI number
- 3005031360
- Establishment type on the cover
- Producer of sterile and non-sterile products
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2 445
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
Personnel conducted aseptic manipulations in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.
Specifically, during production of chromium injection 200 mcg/ml, lot 19K41 l 1, on 13-Nov-19 a technician was observed routinely blocking first pass air by reaching over a tray of sterile stoppers with their hand and forceps. This practice was also observed on 19-Nov-19 dming production of sodium bicarbonate injection 8.4% lot 19L1061.
Observation 2
HEPA filters were not sealed around each perimeter to the support frame.
Specifically,
The "ISO 14664 Cleamoom 107, stated <Redacted B4> Performance Test Report" dated 01/17/18, for ISO-5 sterile fill workstation in room HEPA filters (which were located directly above the ISO-5 workbench) failed filter integrity leak test. The failed result was 17%. The allowable passing leak test cannot be more than <Redacted B4> the · The leak was located along the housing edge of filter . The HEPA filter is measured <Redacted B4> . The section of the housing edge where the leak was located was covered by <Redacted B4> patchofsiricone. According to the Cleanroom Performance Test Report, the patch was 12.6% of the dimension of the HEPA filter.
You failed to investigate to determine if sterile products made since the previous acceptable qualification dated 08/22/17 had been affected prior to patching the filter.
Observation 3
Your facility was designed and/or operated in a way that permits poor flow of materials.
Specifically,
In Room 111, which is classified as ISO-8, empty polypropylene trays are sprayed with non-sterile <Redacted B4> and transferred <Redacted B4> into the ISO-7 classified Room 107, where they are sprayed with sterile <Redacted B4> and placed onto the ISO 5 workbench during aseptic filling operations. There is no specified contact time with the <Redacted B4> disinfectant and no environmental monitoring of the polypropylene trays or <Redacted B4> surface.
Personnel place filled, stoppered vials of drug product into these trays. On 13-Nov-19, a partially filled tray was observed stacked directly on top of a full tray containing filled and stoppered vials of chromium injection 200 mcg/ml, lot 19K4111, which had not yet been capped.
Observation 4
The use of sporicidal agents in the ISO 5 classified aseptic processing area was inadequate and infrequent.
Specifically,
You do not disinfect the perforated stainless-steel benchtop located in the ISO-5 workstation during <Redacted B4> cleaning with sterile <Redacted B4> . According to the Supervisor of Pharmacy Technicians, this benchtop is exposed to sporicide during room fogging, which is performed <Redacted B4> in Room 107 where aspetic filling is performed.
In addition, sporicidal agents are not used for the <Redacted B4> ISO-5 units which are used to store sterile vials.
Observation 5
Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifically,
A. On 19-Nov-19, covered metal trays containing empty finished product vials were transfened from a <Redacted B4> ISO-5 unit, through the ISO-7 Room 107, and into the ISO 5 workstation during aseptic tilling of sodium bicarbonate 8.4%, lot 19Ll 061, without being sanitized.
B. Single use, non-sterile mop heads are used during the <Redacted B4> cleaning of the wall and plexiglass of the ISO-5 aseptic fill workstation in Room 107.
Observation 6
You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically,
There are no dedicated hoods or utensils in the non-sterile processing laboratory where non-hazardous drug products are prepared in the same <Redacted B4> hoods, and with the same utensils, as hazardous drug products.
For example, you have not demonstrated that the Redacted B4> used to wipe down hood <Redacted B4> between uses is capable of deactivating hazardous drug products such as testosterone, progesterone, or estradiol, prior to subsequent weighing of non-hazardous products. In addition, you have not demonstrated the <Redacted B4> detergent used to clean utensils and mixing bowls between uses is capable of deactivating hormone products prior to using these utensils for non-hazardous drug products.
Observation 7
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically,
According to your Raw Material Listing dated 19-Nov-19, you currently use the following dietaiy grade bulk substances in sterile injectable drug products:
Choline Chloride
Alpha Lipoic Acid
Glucosamine HCl
Reduced L-Glutathione (Non-Yeast)
beta-NAD+ [ oxidized form]
The following was observed regarding the use of non-pharmaceutical grade bulk substances in your products:
a) On 10-Jan-19, you initiated a recall of Lipoic Acid 40 mg/ml, 30 ml multi-dose vials, lot 18M0991, BUD 15-Jun-l 9, due to a "filmy/wispy precipitate" found in on-hand vials of released product.
b) You discontinued production of NADH disodium 50 mg/ml after rejecting <Redacted B4> of this product (produced 25-Apr-19 and 08-Oct-19) due to out of specification (OOS) en-in results. You attributed the cause of these results to the raw material, and state in the material review memo <Redacted B4> , dated 18-Oct-19, "NADH raw material is nutraceutical grade", and "it is possible there is variation m presence and quantity of endotoxin from one b-NADH container to the next, within the same vendor's lot".
J
State board of pharmacy records
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Mar 1, 2023: “Through a disciplinary action of the Board, the license is voluntarily surrendered.”, license PHY 43950, case AC 7176, McGuff Compounding Pharmacy Services Inc., Santa Ana, CA. Board list
- Mar 1, 2023: “Through a disciplinary action of the Board, the license is voluntarily surrendered.”, license LSC 99004, case AC 7176, McGuff Compounding Pharmacy Services Inc., Santa Ana, CA. Board list
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 5146 | OSP | McGuff Compounding Pharmacy Services Inc | Santa Ana, CA | Expired |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054014270 | LICENSED PHARMACY | MCGUFF COMPOUNDING PHARMACY SERVICES INC | SANTA ANA, CA | RELINQUISH |
- Nov 4, 2023: “Surrender (Relinquish)”, license 054014270, case 2021011404, MCGUFF COMPOUNDING PHARMACY SERVICES INC, SANTA ANA, CA. Reason given in the record: “pharmacy license voluntarily surrendered as a result of respondent voluntarily surrendering their California pharmacy and compounding pharmacy licenses.” Board list
- Nov 5, 2019: “Reprimand”, license 054014270, case 2018003510, MCGUFF COMPOUNDING PHARMACY SERVICES INC, SANTA ANA, CA. Reason given in the record: “due to sister-state discipline in Alabama for unlicensed practice.” Board list
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.